Bengaluru, Nov. 11 -- Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection 2.4 mg) in India.

The collaboration aims to enhance the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions not currently served by Novo Nordisk India.

Wegovy(R) (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and the reduction of major adverse cardiovascular events in individuals with overweight or obesity. Clinical trials have shown that one in three participants on Wegovy(R) experienced weight loss of ov...